24 . September , 2018 - Monday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Pregabalin

Big Image Pronouncation: (preh-GAB-ah-lin)
Class: Anticonvulsant

Trade Names:
- Capsules 25 mg
- Capsules 50 mg
- Capsules 75 mg
- Capsules 100 mg
- Capsules 150 mg
- Capsules 200 mg
- Capsules 225 mg
- Capsules 300 mg

Mechanism of Action


Mechanism of pregabalin's antinociceptice and antiseizure effects is unknown. Effects may be related to high affinity binding to alpha 2 -delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissue.



Well absorbed after oral administration; bioavailability more than 90%. T max within 1.5 hr. Steady state achieved within 24 to 48 hr.


Vd is approximately 0.5 L/kg. Substrate for system L transporter (transports large amino acids across blood brain barrier.


Negligible metabolism.


T ½ is about 6 hr. Largely eliminated by renal excretion; 90% excreted unchanged in urine.

Special Populations

Renal Function Impairment

Cl nearly proportional to Ccr.


Renal Cl decreases as result of age-related decline in renal function.

Indications and Usage

Management of neuropathic pain associated with diabetic peripheral neuropathy; adjunctive therapy for adults with partial-onset seizures; management of postherpetic neuralgia.


Standard considerations.

Dosage and Administration

Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

PO Initial: 50 mg tid increased to 300 mg/day within 1 wk based on efficacy and tolerability (max, 300 mg/day).


PO Initial: 75 mg bid or 50 mg tid increased to max dose of 300 mg bid or 200 mg tid.

Postherpetic Neuralgia

PO Initial: 75 mg bid or 50 mg tid increased to 300 mg/day within 1 wk based on efficacy and tolerability. May increase up to 300 mg bid or 200 mg tid if necessary and tolerated (max, 600 mg/day).


Taper over 1 wk.

Dosage Adjustment for Renal Impairment

Ccr 60 mL/min or greater: total daily dose range 150 to 600 mg/day administered bid or tid; Ccr 30 to 59 mL/min: total daily dose range 75 to 300 mg/day administered bid or tid; Ccr 15 to 29 mL/min: total daily dose range 25 to 150 mg administered once or twice daily; Ccr less than 15 mL/min: total daily dose range 25 to 75 mg/day administered once daily.

Patients on hemodialysis

Maintenance doses based on Ccr as recommended plus a supplemental post-hemodialysis dose administered after each 4 hr of hemodialysis as follows: if maintenance dose 25 mg once daily, post-dialysis dose is 25 or 50 mg; if maintenance dose is 25 to 50 mg once daily, post-dialysis dose is 50 or 75 mg; if maintenance dose 75 mg once daily, post-dialysis dose is 100 or 150 mg.


Store capsules at controlled room temperature (59° to 86°F).

Drug Interactions

CNS depressants (eg, alcohol, lorazepam, oxycodone)

Additive effects on cognitive and gross motor function have been seen. Avoid alcohol.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Abnormal thinking, amnesia, anxiety, asthenia, ataxia, confusion, depersonalization, dizziness, euphoria, abnormal gait, headache, hypertonia, hypesthesia, incoordination, decreased libido, myoclonus, nervousness, neuropathy, nystagmus, paresthesia, somnolence, speech disorder, stupor, tremor, twitching, vertigo (at least 1%).


Pruritus (at least 1%).


Abnormal vision, blurred vision, conjunctivitis, diplopia, eye disorder (at least 1%).


Abdominal pain, constipation, dry mouth, flatulence, gastroenteritis, vomiting (at least 1%).


Anorgasmia, impotence, urinary frequency, urinary incontinence (at least 1%).


Ecchymosis (at least 1%).


Edema, hypoglycemia, peripheral edema, weight gain (at least 1%).


Arthralgia, back pain, myasthenia (at least 1%).


Bronchitis, dyspnea (at least 1%).


Accidental injury, allergic reaction, increased appetite, chest pain, face edema, flu-syndrome, infection, pain (at least 1%).



Category C .




Safety and efficacy not established.


Because of age-related renal impairment, dosage adjustment is recommended.

Renal Function

Dose reduction recommended.

Hazardous Tasks

May cause dizziness and drowsiness.

Congestive heart failure

Use with caution in patients with NYHA Class III or IV cardiac status.

Creatine kinase elevations

Has been reported. Discontinue pregabalin if myopathy is diagnosed or suspected or if markedly elevated creatine kinase levels occur.

Decreased platelet count

Clinically significant decreases in platelets (20% below baseline and less than 150 x 103/mcL) have been documented.

ECG changes

Mild PR interval prolongation (3 to 6 msec) has been reported; these changes were not associated with an increased risk of PR increases greater than 25% from baseline, on-treatment PR intervals greater than 200 msec, or increased risk of second or third degree block.

Peripheral edema

Has been reported, more frequently in patients taking pregabalin and a thiazolidinedione antidiabetic agent. Use caution with coadministration.

Ophthalmological effects

Reduction in visual acuity, visual field changes, and funduscopic changes have been reported.

Weight gain

Has been reported.



None known.

Patient Information

  • Explain name, dose, action, and potential side effects of drug.
  • Advise patient or caregiver to read the Patient Information leaflet before starting therapy and with each refill.
  • Instruct patient with epilepsy to continue to take other medications for seizures unless advised otherwise by health care provider.
  • Advise patient or caregiver that medication will usually be started at a low dose and then increased as tolerated until maximum benefit has been obtained.
  • Instruct patient or caregiver to take exactly as prescribed and not to change the dose or discontinue therapy unless advised by health care provider.
  • Advise patient to take without regard to meals but to take with food if stomach upset occurs.
  • Advise patient or caregiver that if medication needs to be discontinued it will be slowly withdrawn over a period of 1 wk or more unless safety concerns (eg, rash) require a more rapid withdrawal.
  • Instruct patient to immediately report unexplained muscle pain, tenderness, or weakness, especially if accompanied by general body discomfort or fever.
  • Caution patient that drug may cause dizziness or drowsiness and to use caution while driving or performing other tasks requiring mental alertness or coordination until tolerance is determined.
  • Advise patient that pregabalin may cause visual changes, edema (swelling in feet and/or ankles), and weight gain and to notify health care provider if any of these occur.
  • Caution patient to avoid alcohol, opiates, and other CNS depressants while taking pregabalin because of risk of additive CNS impairment and depressant effects.
  • Advise patient to take frequent sips of water, suck on ice chips or sugarless hard candy, or chew sugarless gum if dry mouth occurs.
  • Instruct women to notify health care provider if pregnant, planning to become pregnant, or breastfeeding.
  • Instruct patient with seizures to notify health care provider if seizures worsen or if new types of seizures occur.
  • Advise patient with epilepsy to carry identification (eg, Medic Alert ) indicating medication usage and epilepsy.
  • Advise patient not to take any prescription or OTC medications, dietary supplements, or herbal preparations unless advised by health care provider.
  • Advise patient or caregiver that follow-up visits and lab tests may be required to monitor therapy and to keep appointments.

Recent Drug Updates at DrugIndexOnline:

Alupent Alupent
Generic name: Metaproterenol sulfate Brand names: Alupent Why is Alupent prescribed? Alupent is a bronchodilator prescribed for the prevention and relief of bronchial asthma and bronchial spasms (wheezing) associated with bronchitis and emphysema. Alupent Inhalation Solution is also used to trea more...

Bumetanide Bumetanide
Some commonly used brand names are: In the U.S.— Bumex 1 Edecrin 2 Lasix 3 Myrosemide 3 In Canada— Apo-Furosemide 3 Edecrin 2 Furoside 3 Lasix 3 Lasix Special 3 Novosemide 3 Uritol 3 Note: For quick reference, the following loop diuretics are numbered to match the correspond more...

dihydroergotamine nasal dihydroergotamine nasal
Generic Name: dihydroergotamine nasal (dye hye droe er GOT a meen) Brand Names: Migranal Nasal Spray What is dihydroergotamine nasal? Dihydroergotamine nasal causes vasoconstriction (narrowing of blood vessels). It also affects blood flow patterns that are associated with migraine and c more...

Epivir tablets, oral solution Epivir tablets, oral solution

Mag 2 Mag 2
Some commonly used brand names are: In the U.S.— Almora 4 Chloromag 1 Citroma 2 Concentrated Phillips' Milk of Magnesia 5 Mag-200 7 Mag-L-100 1 Magonate 4 Mag-Ox 400 7 Mag-Tab SR 6 Magtrate 4 Maox 7 MGP 4 Phillips' Chewable Tablets 5 Phillips' Milk of Magnesia 5 Slow-Mag 1 Uro-Mag 7 In C more...

Maxitrol Ophthalmic Suspension Maxitrol Ophthalmic Suspension
Generic Name: neomycin sulfate, polymyxin B sulfate and dexamethasone Dosage Form: Ophthalmic suspension Maxitrol Description Maxitrol® (neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension) is a multiple dose anti-infective steroid combination in sterile suspension form more...

Metamucil Sugar Free Metamucil Sugar Free
Some commonly used brand names are: In the U.S.— Agoral 35 Alophen 25 Alphamul 30 Alramucil Orange 7 Alramucil Regular 7 Bisac-Evac 25 Black-Draught 26 Black-Draught Lax-Senna 32 Carter's Little Pills 25 Cholac 14 Citroma 16 Citrucel Orange Flavor 3 Citrucel Sugar-Free Orange Flavor 3 Col more...

Nasarel Nasarel
Generic Name: flunisolide nasal (flew NIH so lide) Brand Names: Nasalide, Nasarel What is Nasarel (flunisolide nasal)? Flunisolide is a steroid. It prevents the release of substances in the body that cause inflammation. Flunisolide is used nasally to treat the nasal symptoms of allergie more...